(Q44324857)

2 December 2017

0 references

Pertussis: pertussis control strategies and the options for improving current vaccines (English)

1 reference

2 December 2017

1

Stanley A Plotkin

1 reference

2 December 2017

publication date

4 August 2014

1 reference

Expert Review of Vaccines

2 December 2017

published in

1 reference

2 December 2017

volume

13

1 reference

2 December 2017

issue

9

1 reference

2 December 2017

page(s)

1071-1072

1 reference

Sevenfold rise in likelihood of pertussis test requests in a stable set of Australian general practice encounters, 2000-2011.

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Pertussis re-emergence in the post-vaccination era

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Possible options for new pertussis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Pertussis pathogenesis--what we know and what we don't know

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Bordetella pertussis strains with increased toxin production associated with pertussis resurgence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

The vaccine containing recombinant pertussis toxin induces early and long-lasting protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Nonhuman primate and human challenge models of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

Nonhuman primate model of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.944166

10.1586/14760584.2014.944166

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference